Solomon Steiner

Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT.

Perosphere Pharmaceuticals, Inc. engages in the development of rescue drugs. Its pipeline include Ciraparantag, Felbamate, and Glucagon. The company is headquartered in Danbury, CT.

Cass Pharmaceuticals, Inc. develops pharmaceutical products for diabetes. The company is based in Franklin, TN. The CEO of the company is Stephen J. McCormack.

Perosphere Technologies, Inc. is a private medical technologies company that is focused on developing and commercializing the novel POC (point-of-care) coagulometer. The company is based in Danbury, CT. This diagnostic tool informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. The POC coagulometer is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including direct oral anticoagulants (DOACs). The fast diagnosis and related appropriate treatment decisions the POC coagulometer enables will help establish a new standard of care in hospital emergency departments for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes. The CEO of the company is Sasha H. Bakhru.

Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.

Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ.